期刊文献+

侵袭性肺曲霉菌病8例临床分析 被引量:1

Pulmonary invasive aspergillosis:clinical analysis of 8 cases
下载PDF
导出
摘要 目的总结侵袭性肺曲霉菌病(IPA)的临床特点,以利早期诊断。方法回顾性分析2006年4月至2006年12月解放军总医院呼吸科确诊的8例IPA患者的临床资料。结果本组病例全部经病理诊断为IPA。6/8的患者出现发热症状;1/2的患者具有"新月征"、"气环征"的CT表现;7/8的患者有病灶内空洞或空腔形成;1/2患者痰培养曲霉菌阳性,1/4的患者在病理诊断前痰培养阳性;本组入院前初次诊断正确率为0;本组1例系统性曲霉菌病患者死亡,7例经治疗好转出院。结论IPA的临床症状缺乏特异性,早期具有典型CT表现者较少,痰培养曲霉菌阳性率低,这些原因容易造成早期误诊。因此应关注有基础疾病的患者,对于新发肺部阴影者警惕IPA的可能,对可以耐受经皮肺穿刺或气管镜者,通过尽早病理检查等措施可提高早期诊断率。 Objective To summarize the clinical characteristics of invasive pulmonary aspergillosis(IPA) in order to facilitate diagnosis. Methods The clinical features of 8 cases of IPA from Apr. to Dec. 2006 in our department were analyzed retrospectively. Results Six cases had fever. Crescent sign or ring sign were shown on CT in 4 cases. Seven patients had cavity formation in the focus. In 4 patients, there was positive Aspergillus cultures of sputum, and 2 cases had posifive sputum culture before pathological diagnosis. The correct primary diagnostic rate of IPA was zero before admission. One case died and other 7 cases were improved and discharged. Conclusion The causes of misdiagnosis of IPA are lack of specificity of symptoms and early CT, and low positive rate of culture of sputum. So attention should be paid to the patients with underlying diseases and the possibility of IPA in patients with new shadow in lung. For the patients who can tolerate percutaneous lung puncture or tracheoscopy, pathological examination should be performed in order to improve early diagnosis.
作者 赵微 陈良安
出处 《中华老年多器官疾病杂志》 2007年第5期312-314,共3页 Chinese Journal of Multiple Organ Diseases in the Elderly
关键词 曲霉病 变应性支气管肺 误诊 诊断 aspergillosis, bronchopulmonary misdiagnosis, diagnosis
  • 相关文献

参考文献7

  • 1徐英,董碧蓉.侵袭性曲霉菌病一例[J].临床内科杂志,2005,22(2):117-118. 被引量:1
  • 2朱小敏,周新.侵袭性肺曲霉病的诊断与治疗[J].中国呼吸与危重监护杂志,2005,4(4):316-320. 被引量:36
  • 3[3]Reichenberger F,Habicht JM,Gratwohl A,et al.Diagnosis and treatment of invasive pulmonary aspergillosis in neutropenic patients.Eur Respir J,2002,19:743-755.
  • 4[4]Caillot D,Bassaris H,McGeer A,et al.Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies,chronic granulomatous disease,or AIDS.Clin Infect Dis,2001,33:e83-e90.
  • 5[5]Herbrecht R,Denning DW,Patterson TF,et al.Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.N Engl J Med,2002,347:408-415.
  • 6[6]Mora-Duarte J,Betts R,Rotstein C,et al.Comparison of caspofungin and amphotericin B for invasive candidiasis.N Engl J Med,2002,347:2020-2029.
  • 7[7]Walsh TJ,Raad I,Thomas F,et al.Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy:an externally controlled trial.Clin Infect Dis,2007,44:2-12.

二级参考文献27

  • 1Becker M J, Lugtenburg E J, Cornelissen J J, et al. Galactomannan detection in computerized tomography-based broncho-alveolar lavage fluid and serum in haematological patients at risk for invasive pulmonary aspergillosis. Br J Haematol, 2003; 121:448 ~ 457
  • 2Wingard JR, White MH, Anaissie E, et al. A randomized, double-blind comparative trial evaluating the safety of liposomal amphoteric in B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. Clin Infect Dis, 2000;31:1155~ 1163
  • 3Takemoto K, Yamamoto Y, Ueda Y, et al. Comparative studies on the efficacy of AmBisome and fungizone in a mouse model of disseminated aspergillosis. J Antimicrob Chemother,2004;53:311 ~ 317
  • 4Caillot D. Intravenous itraconazole followed by oral itraconazole for the treatment of amphotericin-B-refractory invasive pulmonary aspergillosis. Acta Haematol, 2003; 109: 111 ~ 118
  • 5Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med ,2002;347:408 ~ 415
  • 6Yuet W. Voriconazole versue amphotericin for primary therapy of invasive aspergillosis. N Engl J Med, 2002; 347: 408 ~ 415
  • 7Petraitiene R, Petraitis V, Groll AH, et al. Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia. Antimicrob Agents Chemother, 2001 ;45: 857 ~ 869
  • 8Taccone FS, Marechal R, Meuleman N, et al. Caspofungin salvage therapy in a neutropenic patient with probable invasive aspergillosis: a case report. Support Care Cancer, 2003; 11: 742 ~744
  • 9Lewis RE, Prince RA, Chi J, et al. Itraconazole preexposure attenuates the efficacy of subsequent amphotericin B therapy in a murine model of acute invasive pulmonary aspergillosis. Antimicrob Agents Chemother,2002;46:3208~ 3214
  • 10Popp AI, White MH, Quadri T, et al. Amphotericin B with and without itraconazole for invasive aspergillosis: a three-year retrospective study. Int J Infect Dis, 1999 ;3:157~ 160

共引文献35

同被引文献2

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部